REGENERON PHARMACEUTICALS, INC. (REGN) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $14.70B; Treasury Stock, Common, ValueUSD $20.57B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-35.80M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $14.40B; Treasury Stock, Common, ValueUSD $19.41B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $11.90M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $13.99B; Treasury Stock, Common, ValueUSD $18.61B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $77.50M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $13.79B; Treasury Stock, Common, ValueUSD $17.94B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $69.00M.
REGENERON PHARMACEUTICALS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Additional Paid in Capital USD | Treasury Stock, Common, Value USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Treasury Stock, Common, Shares shares | Treasury Stock, Value, Acquired, Cost Method USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Treasury Stock, Shares, Acquired shares | Common Stock, Value, Issued USD | Treasury Stock, Value USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Adjustments to Additional Paid in Capital, Other USD | Treasury Stock, Shares shares |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $14.70B | $20.57B | $-35.80M | $37.62B | $31.71B | 36.40M | 3 month · $1.16B 6 month · $1.97B | 3 month · $242.50M | 3 month · 1.70M 6 month · 2.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $14.40B | $19.41B | $11.90M | $36.42B | $31.42B | 34.70M | 3 month · $803.20M | 3 month · $246.90M | 3 month · 1.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $13.99B | $18.61B | $77.50M | $35.80B | $31.26B | 33.70M | (m) | 12 month · $1.00B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $13.79B | $17.94B | $69.00M | $35.05B | $30.96B | 32.70M | 3 month · $663.00M 9 month · $2.79B | 3 month · $241.00M | 3 month · 1.10M 9 month · 4.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $13.49B | $17.28B | $52.50M | $33.68B | $29.94B | 31.60M | 3 month · $1.07B 6 month · $2.12B | 3 month · $254.90M | 3 month · 1.90M 6 month · 3.40M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | $13.19B | $16.22B | $29.10M | $32.38B | $29.39B | 29.70M | 3 month · $1.05B | 3 month · $258.90M | 3 month · 1.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $12.86B | $15.17B | $-7.90M | $31.67B | $29.35B | 28.20M | (m) | 12 month · $996.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $0.00 | $12.70B | $14.19B | $60.20M | $30.76B | $29.33B | 27.00M | 3 month · $738.30M 9 month · $1.64B | 3 month · $230.40M | 3 month · 600.00K 9 month · 1.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $0.00 | $12.32B | $13.46B | $-69.90M | $29.41B | $28.21B | 26.40M | 3 month · $601.40M 6 month · $899.40M | 3 month · $230.00M | 3 month · 600.00K 6 month · 900.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $0.00 | $11.94B | $12.86B | $-77.20M | $27.98B | $26.99B | 25.80M | 3 month · $298.00M | 3 month · $233.30M | 3 month · 300.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $11.35B | $12.56B | $-80.90M | $27.26B | $25.97B | 25.50M | (m) | 12 month · $894.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | $11.25B | $12.27B | $-176.80M | $26.10B | $24.90B | 25.10M | 3 month · $507.10M 9 month · $1.92B | 3 month · $207.40M | 3 month · 700.00K 9 month · 2.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $0.00 | $10.89B | $11.77B | $-197.70M | $25.09B | $24.02B | 24.50M | 3 month · $722.80M 6 month · $1.42B | 3 month · $208.00M | 3 month · 1.00M 6 month · 1.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $0.00 | $10.60B | $11.05B | $-181.60M | $24.12B | $23.50B | 23.50M | 3 month · $693.90M | 3 month · $237.40M | 3 month · 900.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | $9.95B | $10.35B | $-238.80M | $23.31B | $22.66B | 22.60M | (m) | 12 month · $737.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $0.00 | $9.52B | (m) | $-275.10M | $22.11B | $21.44B | (m) | 3 month · $913.00M 9 month · $1.66B | 3 month · $171.10M | 3 month · 1.50M 9 month · 2.70M | (m) | $9.91B | (m) | (m) | (m) | (m) | 22.00M |
| 2022-06-30 | $0.00 | $9.12B | (m) | $-223.80M | $20.79B | $20.69B | (m) | 3 month · $393.60M 6 month · $745.50M | 3 month · $166.00M | 3 month · 700.00K 6 month · 1.20M | (m) | $9.00B | (m) | (m) | (m) | (m) | 20.60M |
| 2022-03-31 | $0.00 | $8.75B | (m) | $-170.10M | $19.94B | $19.91B | (m) | 3 month · $352.00M | 3 month · $165.90M | 3 month · 600.00K | (m) | $8.61B | (m) | (m) | (m) | (m) | 19.94M |
| 2021-12-31 | $0.00 | $8.09B | $8.26B | $-26.20M | $18.97B | $18.77B | 19.40M | (m) | 12 month · $599.20M | (m) | (m) | $8.26B | (m) | (m) | (m) | (m) | 19.40M |
| 2021-09-30 | $0.00 | $7.92B | (m) | $9.50M | $16.74B | $17.26B | (m) | 3 month · $190.50M 9 month · $802.70M | 3 month · $136.40M | 3 month · 300.00K 9 month · 1.60M | (m) | $7.41B | (m) | (m) | (m) | (m) | 17.93M |
| 2021-06-30 | $0.00 | $7.23B | (m) | $15.70M | $15.11B | $15.13B | (m) | 3 month · $288.60M 6 month · $612.10M | 3 month · $135.90M | 3 month · 600.00K 6 month · 1.30M | (m) | $7.22B | (m) | (m) | (m) | (m) | 17.66M |
| 2021-03-31 | $0.00 | $6.89B | (m) | $16.20M | $12.01B | $11.98B | (m) | (m) | 3 month · $135.60M | (m) | (m) | $6.94B | (m) | (m) | (m) | (m) | 17.10M |
| 2020-12-31 | $0.00 | $6.72B | (m) | $29.30M | $10.89B | $11.03B | (m) | (m) | 12 month · $442.90M | (m) | (m) | $6.61B | (m) | (m) | (m) | (m) | 16.43M |
| 2020-09-30 | $0.00 | $6.59B | (m) | $30.80M | $9.74B | $10.13B | (m) | 3 month · $100.40M 9 month · $373.30M | 3 month · $104.60M | 3 month · 200.00K 9 month · 900.00K | (m) | $6.24B | (m) | (m) | (m) | (m) | 15.74M |
| 2020-06-30 | $0.00 | $6.26B | (m) | $35.50M | $8.90B | $9.06B | (m) | 3 month · $0.00 6 month · $272.80M | 3 month · $105.20M | 3 month · 0.00 6 month · 700.00K | (m) | $6.14B | (m) | (m) | (m) | (m) | 15.58M |
| 2020-05-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · $5.00B | (m) | 1 month · 9.81M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $0.00 | $5.21B | (m) | $-9.10M | $8.00B | $12.13B | (m) | 3 month · $336.00M | 3 month · $108.00M | (m) | (m) | $1.07B | (m) | (m) | (m) | (m) | 5.68M |
| 2019-12-31 | $0.00 | $4.43B | (m) | $21.10M | $7.38B | $11.09B | (m) | 12 month · $254.00M | 12 month · $466.90M | 12 month · 722.60K | (m) | $739.90M | (m) | (m) | (m) | (m) | 4.86M |
| 2019-09-30 | $0.00 | $4.39B | (m) | $16.50M | $6.59B | $10.50B | (m) | 3 month · $48.70M | 3 month · $112.70M | (m) | (m) | $488.40M | (m) | (m) | (m) | (m) | 4.17M |
| 2019-06-30 | $0.00 | $4.26B | (m) | $15.80M | $5.92B | $9.76B | (m) | (m) | 3 month · $109.20M | (m) | (m) | $441.80M | (m) | (m) | (m) | (m) | 4.02M |
| 2019-03-31 | $0.00 | $4.16B | (m) | $2.80M | $5.73B | $9.44B | (m) | 3 month · $54.00M | 3 month · $114.80M | (m) | (m) | $444.20M | (m) | (m) | (m) | (m) | 4.05M |
| 2018-12-31 | $0.00 | $3.91B | (m) | $-12.30M | $5.25B | $8.76B | (m) | 12 month · $80.20M | 12 month · $444.80M | (m) | (m) | $396.40M | (m) | (m) | (m) | (m) | 3.99M |
| 2018-09-30 | $0.00 | $3.84B | (m) | $-10.52M | $4.43B | $7.87B | (m) | 3 month · $42.60M | 3 month · $116.50M | (m) | (m) | $396.37M | (m) | (m) | (m) | (m) | 3.99M |
| 2018-06-30 | $0.00 | $3.71B | (m) | $-11.61M | $3.84B | $7.19B | (m) | 3 month · $37.60M 6 month · $37.60M | 3 month · $113.10M | (m) | (m) | $353.85M | (m) | (m) | (m) | (m) | 3.89M |
| 2018-03-31 | $0.00 | $3.61B | (m) | $-15.59M | $3.29B | $6.57B | (m) | (m) | 3 month · $85.80M | (m) | (m) | $316.24M | (m) | (m) | (m) | (m) | 3.76M |
| 2017-12-31 | $0.00 | $3.51B | (m) | $600.00K | $2.95B | $6.14B | (m) | (m) | 12 month · $524.60M | (m) | (m) | $316.20M | (m) | (m) | (m) | (m) | 3.76M |
| 2017-09-30 | $0.00 | $3.57B | (m) | $23.84M | $2.77B | $6.05B | (m) | (m) | (m) | (m) | (m) | $316.24M | (m) | (m) | (m) | (m) | 3.76M |
| 2017-06-30 | $0.00 | $3.45B | (m) | $2.35M | $2.38B | $5.52B | (m) | (m) | (m) | (m) | (m) | $316.24M | (m) | (m) | (m) | (m) | 3.76M |
| 2017-03-31 | $0.00 | $3.19B | (m) | $-5.88M | $2.00B | $4.87B | (m) | (m) | (m) | (m) | (m) | $316.24M | (m) | (m) | (m) | (m) | 3.76M |
| 2016-12-31 | $0.00 | $3.03B | (m) | $-12.84M | $1.75B | $4.45B | (m) | 12 month · $0.00 | 12 month · $574.90M | (m) | (m) | $316.24M | (m) | 12 month · $47.80M | (m) | 12 month · $-643.30M | 3.76M |
| 2016-09-30 | $0.00 | $3.31B | (m) | $-2.90M | $1.50B | $4.49B | (m) | (m) | (m) | (m) | (m) | $316.05M | (m) | (m) | (m) | (m) | 3.76M |
| 2016-06-30 | $0.00 | $3.16B | (m) | $5.20M | $1.23B | $4.08B | (m) | (m) | (m) | (m) | (m) | $316.05M | (m) | (m) | (m) | (m) | 3.76M |
| 2016-03-31 | $0.00 | $3.05B | (m) | $4.36M | $1.02B | $3.77B | (m) | (m) | (m) | (m) | (m) | $307.48M | (m) | (m) | (m) | (m) | 3.66M |
| 2015-12-31 | $0.00 | $3.10B | (m) | $8.57M | $852.70M | $3.65B | (m) | 12 month · $0.00 | 12 month · $464.02M | (m) | (m) | $306.07M | (m) | 12 month · $819.66M | (m) | 12 month · $-449.46M | 3.64M |
| 2015-09-30 | $0.00 | $2.88B | (m) | $7.72M | $697.71M | $3.30B | (m) | (m) | (m) | (m) | (m) | $288.78M | (m) | (m) | (m) | (m) | 3.44M |
| 2015-06-30 | $0.00 | $3.12B | (m) | $19.15M | $487.31M | $3.34B | (m) | (m) | (m) | (m) | (m) | $287.08M | (m) | (m) | (m) | (m) | 3.42M |
| 2015-03-31 | $0.00 | $2.81B | (m) | $47.90M | $292.67M | $2.97B | (m) | (m) | (m) | (m) | (m) | $181.82M | (m) | (m) | (m) | (m) | 2.16M |
| 2014-12-31 | $0.00 | $2.45B | (m) | $52.25M | $216.64M | $2.55B | (m) | 12 month · $0.00 | 12 month · $326.81M | (m) | (m) | $169.53M | (m) | 12 month · $691.87M | (m) | 12 month · $-294.55M | 2.02M |
| 2014-09-30 | $0.00 | $2.42B | (m) | $26.89M | $145.21M | $2.55B | (m) | 9 month · $0.00 | 9 month · $229.69M | (m) | (m) | $43.85M | (m) | 9 month · $156.66M | (m) | 9 month · $-143.04M | 521.89K |
| 2014-06-30 | $0.00 | $2.34B | (m) | $4.26M | $65.49M | $2.37B | (m) | 6 month · $0.00 | 6 month · $155.14M | 6 month · 521.88K | (m) | $-43.85M | (m) | 6 month · $-156.65M | (m) | 6 month · $-143.04M | 521.88K |
| 2014-03-31 | $0.00 | $2.24B | (m) | $1.47M | $-27.25M | $2.21B | (m) | (m) | 3 month · $82.98M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $0.00 | $2.05B | (m) | $-1.19M | $-92.69M | $1.96B | (m) | (m) | 12 month · $217.08M | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | 0.00 |
| 2013-09-30 | (m) | $1.88B | (m) | $-2.85M | $-189.50M | $1.69B | (m) | (m) | 9 month · $144.81M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $1.83B | (m) | $-3.43M | $-330.80M | $1.49B | (m) | (m) | 6 month · $98.73M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $1.83B | (m) | $-1.64M | $-418.18M | $1.41B | (m) | (m) | 3 month · $53.55M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $0.00 | $1.76B | (m) | $-1.17M | $-517.05M | $1.26B | (m) | (m) | 12 month · $94.18M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $1.80B | (m) | $-1.90M | $-987.46M | $806.02M | (m) | (m) | 9 month · $63.51M | (m) | $94.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $0.00 | $1.78B | (m) | $-2.37M | $-1.18B | $594.66M | (m) | (m) | 6 month · $42.85M | (m) | $94.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $1.76B | (m) | $-1.34M | $-1.26B | $-30.79M | (m) | (m) | 3 month · $23.45M | (m) | $93.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $0.00 | $1.75B | (m) | $-1.86M | $-1.27B | $485.73M | (m) | (m) | 12 month · $56.61M | (m) | $91.00K | (m) | 12 month · $120.62M | (m) | 12 month · $93.80M | (m) | (m) |
| 2011-10-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · $120.60M | (m) | (m) | (m) | (m) |
| 2011-09-30 | $0.00 | $1.64B | (m) | $-1.73M | $-1.21B | $428.25M | (m) | (m) | 9 month · $40.77M | (m) | $90.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | $0.00 | $1.63B | (m) | $-904.00K | $-1.15B | $478.03M | (m) | (m) | 6 month · $27.39M | (m) | $89.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | $0.00 | $1.61B | (m) | $-2.17M | $-1.09B | $518.09M | (m) | (m) | 3 month · $14.90M | (m) | $89.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $0.00 | $1.58B | (m) | $-2.49M | $-1.05B | $527.82M | (m) | (m) | 12 month · $39.90M | (m) | $87.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | $0.00 | $1.38B | (m) | $-175.00K | $-1.03B | $348.06M | (m) | (m) | (m) | (m) | $80.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | $0.00 | $1.37B | (m) | $-306.00K | $-997.09M | $371.22M | (m) | (m) | (m) | (m) | $80.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | $386.27M | (m) | (m) | 3 month · $8.83M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $2.00K | $1.34B | (m) | $1.04M | $-941.10M | $396.76M | (m) | (m) | 12 month · $31.26M | (m) | $79.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | $422.44M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | $410.51M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | $421.51M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | (m) | (m) | (m) | $459.35M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |